Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations

Details 詳細情報について

• CRID

  1360574096179259520

• DOI

  10.1097/jto.0b013e318202bffe

• ISSN

  15560864

• Web Site

  https://api.elsevier.com/content/article/PII:S1556086415322139?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S1556086415322139?httpAccept=text/plain

• Data Source

  • Crossref